PMID- 8226460
OWN - NLM
STAT- MEDLINE
DCOM- 19931203
LR  - 20171213
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 75
IP  - 2
DP  - 1993 Aug
TI  - NG-monomethyl-L-arginine does not restore loss of hypoxic pulmonary 
      vasoconstriction induced by TNF-alpha.
PG  - 618-25
AB  - Tumor necrosis factor-alpha (TNF-alpha) causes systemic hypotension, pulmonary 
      vasodilation, and loss of hypoxic pulmonary vasoconstriction. 
      NG-monomethyl-L-arginine (L-NMMA) inhibits nitric oxide (NO) production and 
      prevents some systemic manifestations of TNF-alpha. We tested using an isolated 
      perfused canine lobe whether NO also mediates the pulmonary vascular effects of 
      TNF-alpha. Total resistance (RT) was measured during control and hypoxic 
      ventilation over a 90-min period in six control lobes, five lobes treated with 
      TNF-alpha (250 micrograms), six lobes treated with L-NMMA (200 mg), and five 
      lobes treated with L-NMMA (200 mg) + TNF-alpha (250 micrograms). In the control 
      lobes RT increased (P < 0.02) from 0.0474 +/- 0.0105 to 0.0677 +/- 0.0133 
      cmH2O.ml-1 x min during normoxic and hypoxic ventilation, respectively. RT 
      decreased (P < 0.05) from a baseline of 0.0593 +/- 0.0133 to 0.0449 +/- 0.0176 
      cmH2O.ml-1 x min 30 min after TNF-alpha administration and did not further change 
      during hypoxic ventilation (0.0475 +/- 0.0107 cmH2O.ml-1 x min). L-NMMA 
      pretreatment did not prevent the TNF-alpha-induced loss of hypoxic pulmonary 
      vasoconstriction, with values of RT unchanged from normoxic (0.0541 +/- 0.0067 
      cmH2O.ml-1 x min) to hypoxic (0.0545 +/- 0.0078 cmH2O.ml-1.min) ventilation (P > 
      0.10) in the L-NMMA + TNF-alpha group after TNF-alpha administration. We conclude 
      that NO is not the mediator responsible for the acute pulmonary vascular effects 
      of TNF-alpha.
FAU - Johnson, D
AU  - Johnson D
AD  - Department of Medicine, University of Saskatchewan, Saskatoon, Canada.
FAU - Hurst, T
AU  - Hurst T
FAU - Wilson, T
AU  - Wilson T
FAU - Murphy, F
AU  - Murphy F
FAU - Saxema, A
AU  - Saxema A
FAU - To, T
AU  - To T
FAU - Mayers, I
AU  - Mayers I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 27JT06E6GR (omega-N-Methylarginine)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
RN  - DCR9Z582X0 (Epoprostenol)
SB  - IM
MH  - Animals
MH  - Arginine/*analogs & derivatives/pharmacology
MH  - Blood Cell Count
MH  - Blood Gas Analysis
MH  - Blood Pressure/physiology
MH  - Dogs
MH  - Epoprostenol/pharmacology
MH  - Filtration
MH  - Granulocytes/physiology
MH  - Hypoxia/*physiopathology
MH  - Nitric Oxide/*antagonists & inhibitors/physiology
MH  - Perfusion
MH  - Pulmonary Circulation/*drug effects
MH  - Pulmonary Wedge Pressure/drug effects
MH  - Respiration, Artificial
MH  - Tumor Necrosis Factor-alpha/*pharmacology
MH  - Vascular Resistance/physiology
MH  - Vasoconstriction/*drug effects
MH  - omega-N-Methylarginine
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
AID - 10.1152/jappl.1993.75.2.618 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 1993 Aug;75(2):618-25. doi: 10.1152/jappl.1993.75.2.618.